270 related articles for article (PubMed ID: 24468298)
1. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
2. Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Oberguggenberger A; Meraner V; Sztankay M; Beer B; Weigel G; Oberacher H; Kemmler G; Czech T; Holzner B; Wildt L; Sperner-Unterweger B; Daniaux M; Hubalek M
BMC Cancer; 2017 Mar; 17(1):226. PubMed ID: 28351392
[TBL] [Abstract][Full Text] [Related]
3. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
4. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
5. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Pfeiler G; Königsberg R; Hadji P; Fitzal F; Maroske M; Dressel-Ban G; Zellinger J; Exner R; Seifert M; Singer C; Gnant M; Dubsky P
Br J Cancer; 2013 Sep; 109(6):1522-7. PubMed ID: 24002592
[TBL] [Abstract][Full Text] [Related]
6. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
[TBL] [Abstract][Full Text] [Related]
7. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Kyvernitakis I; Knöll D; Struck M; Hars O; Bauer T; Hadji P
J Cancer Res Clin Oncol; 2014 Jan; 140(1):159-66. PubMed ID: 24292402
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Beer B; Schubert B; Oberguggenberger A; Meraner V; Hubalek M; Oberacher H
Anal Bioanal Chem; 2010 Oct; 398(4):1791-800. PubMed ID: 20730580
[TBL] [Abstract][Full Text] [Related]
9. Effect of simvastatin on the pharmacokinetics of anastrozole.
Bao T; Blackford AL; Stearns V
Breast Cancer Res Treat; 2012 Jan; 131(2):709-11. PubMed ID: 22089963
[TBL] [Abstract][Full Text] [Related]
10. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Ingle JN; Kalari KR; Buzdar AU; Robson ME; Goetz MP; Desta Z; Barman P; Dudenkov TT; Northfelt DW; Perez EA; Flockhart DA; Williard CV; Wang L; Weinshilboum RM
Steroids; 2015 Jul; 99(Pt A):32-8. PubMed ID: 25163006
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
[TBL] [Abstract][Full Text] [Related]
12. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
13. Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index.
Coscia EB; Sabha M; Gerenutti M; Groppo FC; Bergamaschi CC
Rev Bras Ginecol Obstet; 2017 Jan; 39(1):14-20. PubMed ID: 28187491
[No Abstract] [Full Text] [Related]
14. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
16. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Sestak I; Distler W; Forbes JF; Dowsett M; Howell A; Cuzick J
J Clin Oncol; 2010 Jul; 28(21):3411-5. PubMed ID: 20547990
[TBL] [Abstract][Full Text] [Related]
17. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
[TBL] [Abstract][Full Text] [Related]
18. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
[TBL] [Abstract][Full Text] [Related]
19. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
[TBL] [Abstract][Full Text] [Related]
20. Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.
Mareck U; Geyer H; Guddat S; Haenelt N; Koch A; Kohler M; Opfermann G; Thevis M; Schänzer W
Rapid Commun Mass Spectrom; 2006; 20(12):1954-62. PubMed ID: 16715475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]